The Asia-Pacific Dengue Prevention Board organized a meeting (Kuala Lumpur, Malaysia, 1–2 June 2016) to highlight points for consideration about CYD-TDV vaccine introduction and to define the most useful tools and approaches for dengue endemic countries to develop policies.
We invite you to read the full report on the "Development of Dengue Vaccines: Issues relating to dengue vaccine introduction in light of the WHO SAGE recommendations" here.
Please click here for the Dengue Vaccine Initiative (DVI) full statement.
Today, July 10, Sanofi Pasteur published in The Lancet the results of the first of two Phase 3 clinical trials for its dengue vaccine candidate — a live attenuated chimeric tetravalent vaccine. The study is a randomized, observer-blind, placebo-controlled multicenter trial involving 10,275 children aged 2 to 14 years in Indonesia, Malaysia, the Philippines, Thailand and Vietnam.
An Initial Examination of Results
The data from this trial showed moderate efficacy of 57% against any virologically-confirmed dengue and that efficacy against serotypes 1, 2, 3 and 4 is 50%, 35%, 78% and 75%, respectively. Vaccine efficacy was statistically significant for all serotypes except serotype 2. The reason behind variable vaccine efficacy is still unknown, inviting further in depth examination and analysis.
The vaccine efficacy against dengue hemorrhagic fever was higher than 80 percent and the efficacy against hospitalized dengue was 67 percent in the age group that was studied between the ages of 2 and 14 in the five countries in Asia. These are both encouraging results.
This trial also further reassures the safety of CYD-TDV in the first 12 months following the primary vaccine series, as results showed no signals of an increase in serious adverse events in the trial during the two years following the administration of vaccine.
Follow-Up: A Fuller Assessment
A fuller assessment of the efficacy of the vaccine will help us better understand the performance of this dengue vaccine candidate.
However, these results help us better comprehend the complexities and challenges of developing a dengue vaccine. They help pave the way for further research in the dengue vaccine development community.
Additionally, the results of the second pivotal efficacy trial in Latin America, which will be available at the end of 2014, will help complement these data from Asia and provide a wider lens of analysis for a global vaccine.
In the meantime, other vaccine candidates continue to advance through the pipeline. Two of them, one developed by Takeda, and another one by the U.S. National Institutes of Health and the Butantan Institute in Brazil, are currently undergoing Phase 2 trials. Merck, with ISCOM, and GlaxoSmithKline, with the Oswaldo Cruz Foundation, are conducting Phase 1 trials of their own vaccine candidates
Currently, no cure or treatment exists for dengue. As dengue cases rise — putting nearly half of the world’s population at risk — so does the urgent need for a preventive intervention. A safe, effective and affordable dengue vaccine would represent a major advance for the prevention of this disease and alleviate its burden on low and middle-income countries, where the disease is endemic.
For a full Q&A by the World Health Organization (WHO), please click here.